Detalles de la búsqueda
1.
Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Eur Urol
; 68(2): 256-62, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25794457
2.
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
Eur Urol
; 67(3): 508-16, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25301758
3.
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Eur Urol
; 52(5): 1398-406, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17485161
4.
Comentario editorial: Cirugía reconstructiva para residentes en Urología / Publishing comment: Reconstructive surgery for residents in Urology
Arch. esp. urol. (Ed. impr.)
; 63(7): 493-494, sept. 2010.
Artículo
en Español
| IBECS (España) | ID: ibc-83183
5.
Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.
J Urol
; 174(4 Pt 1): 1242-7, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16145378
Resultados
1 -
5
de 5
1
Próxima >
>>